Specialised Therapeutics’ breast cancer drug gets Philippines FDA approval
Pharmaceutical Technology
JULY 8, 2022
Specialised Therapeutics’ oral drug, Nerlynx (neratinib) has obtained the Philippines Food and Drug Administration approval to lower the recurrence or mortality risk in early-stage HER2-positive (HER2+) breast cancer patients. The trial demonstrated that after a median follow-up of 5.2
Let's personalize your content